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The latent period between exposure to carcinogen and development of cancer 
in  a  given  individual  can  range  from  a  few  years  to  several  decades.  Even 
genetically  identical  mice  treated  with  the  same  dose  of carcinogen  under 
controlled experimental conditions develop tumors after greatly different latent 
periods. It is, therefore, puzzling why patients that have developed one cancer 
are at a  much increased risk of developing a  second cancer within a  relatively 
short time (1-4).  One mechanism that might lead to the successive appearance 
of multiple primary malignancies was  suggested by  our  experimental studies 
involving the ultraviolet light (UV)1-induced fibrosarcoma, 1591-RE.  Like most 
UV-induced cancers (5), this tumor consists of "potentially malignant," "prema- 
lignant," or "regressor" cells that grow in immunodeficient  mice but are regularly 
rejected by normal hosts. In rare instances, heritable variants arise that have lost 
tumor antigens, and these tumors do grow progressively in normal hosts (6). In 
the present study, we made a striking and puzzling observation when mice were 
challenged with  the  premalignant  1591-RE  cells  at  two  anatomically distinct 
locations. In the rare animals that developed one progressively growing tumor, 
a second tumor regularly emerged at the other location a short time later. This 
led us to ask if the development of one tumor could facilitate the outgrowth at 
another location of a second cancer from premalignant cells.  Our results show 
that indeed this occurs and that the first cancer enhances immunologically the 
outgrowth of other cancers from premalignant cells. 
Materials and Methods 
Mice.  5-10-wk-old female C3H/HeN  (MTV-, mammary tumor virus-negative) and 
female BALB/cAn mice from colonies of germfree-derived, specific pathogen-free ani- 
mals were purchased from the NCI Frederick Cancer Research Facility. They were kept 
at the La Rabida Institute in laminar air flow hoods and were given sterilized food (Purina 
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i Abbreviations used in this paper:  C', complement; CMEM, complete minimum  essential medium; 
CTL, cytotoxic T  lymphocytes; MCA, methylcholanthrene; MLTC, mixed lymphocyte-tumor cell 
culture; MTV, mammary tumor virus; TBA, tumor-bearing  animal; UV, ultraviolet light. 
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5010 C; Purina,  Inc., St.  Louis,  MO) and water.  The original stock of nude C3H mice 
was in its 23rd backcross generation when obtained from a colony at the Biology Division 
of the Oak Ridge National Laboratory. Unless otherwise specified, the abbreviation TBA 
refers to animals bearing an established progressor tumor >0.7 and <1.2 cm in average 
diameter (>0.5 and <1.5 cm  s in volume). 
Fibrosarcoma  Lines.  The  fibrosarcomas  1591-RE,  1316-RE,  2240-RE,  2237-PRO 
(clone 42), 948-PRO, and 968-PRO were induced in C3H/HeN MTV- mice by repeated 
exposure to UV light (5).  The fibrosarcomas  1130-RE and  3152-PRO were induced in 
UV-irradiated  C3H/HeN MTV- mice by the subcutaneous injection of 3-methylcholan- 
threne under the ventral non-UV-exposed skin. Tumors with the postscript "-RE" were 
strongly immunogenic in  that  they  regressed  after  an  initial  1-2  wk  of growth.  This 
phenomenon of regression  occurred even when large numbers of the tumor cells (e.g., 
multiple 1-mm  3 tumor fragments) were injected, although the same tumor inoculum grew 
and  killed  nude  mice  or  mice  immunosuppressed  by  x  irradiation.  Tumors  with  the 
postscript  "-PRO"  grew  progressively  in  (and  killed)  normal  syngeneic  mice.  Tumors 
2237-PRO,  968-PRO,  948-PRO, and  3152-PRO are tumors that grew progressively in 
normal mice in the first transplant generation. The fibrosarcomas 1591-PRO, 1316-PRO, 
and  1130-PRO are progressively growing variants of 1591-RE,  13 l 6-RE, and  1130-RE, 
respectively;  these  variants  arose  spontaneously  after  transplantation  of the  regressor 
tumors into normal mice.  1590-PRO has been referred to previously (6) as  1591-PRO.4 
and has lost the "A" antigen while retaining the B antigen (7).  1591-ASBS is a progressor 
variant of 1591-RE, sequentially selected in vitro with a cloned anti-A and then anti-B T 
cell line; this variant lacks the A and the B antigens and has previously been referred to 
as 1591-V5 (7).  K 101-RE is a  UV-induced BALB/c fibrosarcoma and P815 is a mastocy- 
toma that spontaneously arose in DBA/2 mice.  Using previously described (6) methods 
tumors  were  readapted  to growth  in  vitro,  expanded  in  tissue  culture  within  2  wk of 
explantation,  and  cryopreserved  in  aliquots.  Cells  were cultured  in  minimum  essential 
medium containing 10% heat-inactivated fetal bovine serum (CMEM).  Whenever tumor 
cells were required  for experiments,  frozen aliquots were thawed and used within  48 h. 
For tumor challenges, solid tumors grown in nude C3H mice were implanted subcutane- 
ously as viable  1-mm  3 fragments with a  13 gauge trocar, or suspensions of cultured cells 
were injected subcutaneously in 0.2 ml of CMEM.  15 min before surgery mice received 
0.5 mg of sodium pentobarbital  intraperitoneally.  Deep anesthesia  was then induced by 
inhaled ethyl ether and tumors were removed by dissection of their margins. 
Generation  of Cytotoxic Lymphocytes In  Vitro.  Tumor-specific cytotoxic T  lymphocytes 
(CTL) were generated  from spleen  cells of animals immunized with either three  l-ram 3 
fragments of solid viable tumor or a single subcutaneous injection of 107 viable cultured 
tmnor cells.  Spleen cells were restimulated in vitro with the immunizing tumor in a mixed 
lymphocyte-tumor culture (MLTC) as previously described (6).  Alloantigen-specific cy- 
tolytic cells were generated by culturing nonimmune C3H/HeN spleen cells for 6 d  with 
2,000-rad x-irradiated BALB/c spleen cells.  Cytotoxicity was determined by the ability of 
effectors to lyse 5~Cr-labeled  target cells during a  6  h  assay as previously described (6). 
The percentage of specific lysis was calculated by the formula: [(experimental  release  - 
spontaneous release)/(total  release -  spontaneous release)] ×  100. 
Adoptive  Transfer Assay.  Lethally (800 tad) x-irradiated  mice received,  3-24 h  later, 
spleen cells, intravenously, and tumor fragments, subcutaneously. Spleens were removed 
from donor mice using sterile techniques, homogenized in a glass tissue grinder, filtered 
through nylon mesh, centrifuged,  and resuspended  in CMEM.  Recipients received one- 
third organ equivalents (about  3  ×  107 spleen  cells)  in 0.25 ml CMEM.  In some experi- 
ments,  the  spleen  cells  of  the  tumor-bearing  animals  were  treated  with  designated 
antibodies and complement or complement alone before transfer.  Absorbed rabbit com- 
plement and monoclonal antibody at approproate concentrations were added to 107 spleen 
cells in  1 ml CMEM.  The mixture was incubated for 30 rain at 37°C, then centrifuged, 
resuspended, and treated again with the complement and antibody the same way. Mono- 
clonal anti-Thy-1.2 (AT83A) and anti-Ly-2.1 (GS3.168) supernatants (8) (gift of Dr. Frank 
Fitch,  University of Chicago) were used at a dilution of 1 : 10, which eliminates standard MULLEN  ET  AL.  1667 
control cells.  Adherent cells  were removed by suspending  spleen cells  at  l0  s cells/ml 
CMEM  into  which  200  mg  of sterile  carbonyl  iron  particles  had  been  added.  The 
suspension was placed in a 10 cm diam petri dish and incubated 60 rain at 37°C; the iron 
was then moved to one side with a strong magnet and the remaining nonadherent cells 
were removed, centrifuged, and washed once in CMEM. 
Results 
Successive  Development  of Progressing  Tumors  at Anatomically  Distinct Injection 
Sites  in  the  Same  Animal.  When  100  normal  immunocompetent  mice  were 
engrafted in  both the right and  left inguinal  regions with the regressor tumor 
1591-RE  (fifth transplant  generation  in  x-irradiated  thymectomized mice),  95 
mice rejected both tumor challenges.  Curiously,  in  5  mice, when progressively 
growing tumors arose at one of the two engraftment sites, a second progressively 
growing tumor also developed at the other injection site 2-3 wk later. Probability 
analysis  ~ (9) showed that this phenomenon is incompatible with a model in which 
the occurrence of a second tumor is independent of the occurrence of the first, 
suggesting that either the recipient mice showing progressive tumor growth had 
less  immunological resistance  than  the  rest of the  mice,  or that  growth of the 
first malignancy promoted the growth of the other later-appearing tumor. When 
the bilateral tumors were individually transplanted into normal mice the tumor 
that  had appeared  first always  grew  out at a  higher incidence than  the tumor 
that  had  emerged  later.  The  comparative 
second tumors reisolated from each of the 
into normal mice were 6/12 vs.  1/12,  8/10 
same  tumors  transplanted  into  nude  mice 
(5/5  vs.  5/5,  4/4 vs.  4/4, and  2/2  vs.  2/2). 
tumor  incidences  for  the  first  and 
three mice tested and transplanted 
vs. 4/10, and 5/6 vs.  2/6, while the 
as  controls  showed  no  differences 
In summary, an average of 68%  of 
first-appearing tumors grew while only 25% of grafts from the later tumors grew 
in  normal  mice (P <  0.01),  suggesting that  the second-appearing tumors were 
less malignant and possibly more immunogenic than the first-appearing tumor. 
The  above  experiments  suggested  the  possibility  that  an  established  tumor 
may facilitate the growth of a  second tumor in the same host.  In the following 
experiments,  we  therefore  determined  whether  the  1591-PRO  tumor  would 
grow faster in mice already carrying an established 1591-PRO tumor at a second 
site.  Thus,  5  x  106  1591-PRO  tissue  culture  cells  were  injected  into  normal 
tumor-free mice or into  1591-PRO TBA.  In two independent experiments, the 
tumor inocula grew significantly faster in  the TBA and achieved volumes in  1 
mo that were two to six times greater than those in the controls. 3 Thus, animals 
already bearing a tumor on one site show an enhanced growth of a second tumor 
transplanted later into the same host at a different site. 
Regressor Cells Grew Progressively in Animals Bearing a Progressor Tumor.  The 
above experiments suggested that an established progressor tumor could facili- 
tate  the  growth  of a  second  progressor  tumor  in  the  same  animal.  We  next 
determined the strength of this facilitation and its specificity. We analyzed first 
,a Assuming that cases of progressive tumor growth are independent of one another, the probability 
that the second five tumors would emerge in the animals growing the first five tumors is: P  =  (5  x 
4x3x2x  1)/(100 x  99 x  98 x  97 x  96)--  1.3x  10  -~. 
3 0.99 +  0.14 cm  "~ for TBA compared with 0.44 _+ 0.15 cm  3 for controls (7 mice per group); and 
1.20 +  0.59 cm  ~ for TBA compared with 0.23 +- 0.06 cm  3 for controls (5 and 3  mice per group); P 
<  0.01  in both experiments using Student's t test. 1668  MULTIPLE CANCERS AND  IMMUNE  SUPPRESSION 
whether the facilitation was strong enough to allow the outgrowth of even highly 
immunogenic  1591-RE tumor cells.  Table I shows that  1591-RE regressor cells 
indeed developed into progressively growing tumors in most of the  1591-PRO- 
bearing mice but failed to grow progressively in normal mice. Since  1591-PRO 
was  derived  from  1591-RE  and  thus  belongs  to  the  same  tumor  lineage,  we 
explored whether regressor tumor cells other than  1591-RE could also be made 
to  grow  out  in  mice  bearing  1591-PRO.  Table  I  shows  that  the  1591-PRO 
tumor-bearing state did indeed facilitate the outgrowth of two other syngeneic 
tumors that ordinarily regress; however,  1591-PRO TBA rejected the allogeneic 
mastocytoma P815. 
These experiments showed that  1591-PRO facilitated the outgrowth of several 
independently derived syngeneic regressor tumors. We next determined (Table 
II) whether  progressor  tumors  other  than  1591-PRO  could  also  induce  such 
facilitation.  We found that this was indeed the case for most progressor tumors 
whether they had been induced by either UV or MCA or whether the progressor 
phenotype had been found in the primary isolate or had developed as a  variant 
during subsequent  transplant generations.  Viewed together,  these experiments 
suggest  (a)  that  facilitation  of tumor  growth  is  very strong  since  it  causes  the 
outgrowth  of highly immunogenic,  potentially malignant cells, and (b) that this 
facilitation  is  induced  by most independently  derived  tumors.  However,  there 
were certain exceptions to this general rule: For example, 2237-PRO facilitated 
the  outgrowth  of  both  1591-RE  and  l l30-RE,  while  l l30-PRO  facilitated 
growth of 1591-RE but not  1130-RE.  Such exceptions will be discussed further 
below.  Also,  Table  III shows  that  the  progressor tumors  must reach a  certain 
volume before they effectively facilitated the outgrowth of a later challenge with 
regressor cells. However, multiple small tumors that had grown for a short time 
were as effective as single large tumors that had grown for a  longer time. Thus, 
the size of the burden  was more important than  the duration  of the progressor 
tumor implant in facilitating the outgrowth of regessor tumor cells. 
TABLE  I 
Highly Immunogenic, Potentially Malignant Cells Grow 
in Tumor-bearing but Not Normal Mice 
Tumor challenge* 
Tumor incidence in:* 
Nude mice  Normal mice  TBA 
1591-RE  8/8 (100)  0/20 (0)  27/30 (90)  ~ 
1316-RE  9/9 (100)  0/10 (0)  17/21 (81)§ 
2240-RE  2/2(100)  0/5  (0)  2/3  (67) 
P815 (Allogeneic)  7/7 (100)  0/14 (0)  0/10 (0) 
* Three  l-ram  a regressor  tumor fragments  were injected subcutaneously into normal  mice, nude 
mice, or mice that had borne 1591-PRO for 3-4 wk (average volume, 0.5 cmS). All tumors were 
syngeneic, UV-induced regressor fibrosarcomas, with the exception of P815, which is an allogeneic 
(H-2  d) spontaneous mastocytoma. 
* Numbers  of animals  with progressively growing  tumors  per  number challenged  (percent  in 
parentheses). Tumor incidence was determined  5 wk after challenge with regressor  tumor. All 
animals that had tumors at 5 wk eventually died because of progressive tumor growth.  Data are 
pooled from four experiments for 1591-RE, three experiments for 1316-RE, two experiments for 
P815, and one experiment for 2240-RE. 
§ Tumor incidence differs significantly from that in normal mice (P < 0.001). MULLEN  ET  AL. 
TABLE  II 
Several Different Progressor Tumors Can Facilitate the Outgrowth of 
Highly Immunogenic Tumor Cells 
Progressor tumor burden*  Regressor tumor challenge  ~ 
Name  Inducing  Name  Incidence 
agent 
1316-PRO  UV  1591-RE  12/20 (60)  81 
1316-RE  3/8  (38)  8 
None  1591-RE  1/8  (13) N 
1316-RE  0/7  (0) 
2237-PRO  UV  159 I-RE  8/10 (80)  8 
1130-RE  8/10 (80)  8 
None  1501-RE  0/5  (0) 
1130-RE  0/5  (0) 
968-PRO  U V  1591-RE  5/13 (38)  8N 
1130-RE  3/8  (38)  81 
None  1591-RE  0/5  (0) | 
ll30-RE  0/5  (0) n 
948-PRO  UV  1591-RE  0/9  (0) | 
None  0/9  (0) ~ 
1130-PRO  M CA  1591-RE  5/10 (50)  8u 
1130-RE  0/10 (0) u 
None  1591-RE  1/10 (10) u 
11~0-R~  0/10 (0) ~ 
3152-PRO  MCA  159 I-RE  6/10 (60)  8 
None  0/5  (0) 
1591-ASBS  UV  1591-RE  3/5  (60)  8 
None  0/5  (0) 
* Mice were challenged with progressor tumors that grew to at least 0.5 
cm  3 before the host was challenged with regressor tumors.  Progressor 
tumors were induced by ultraviolet light (UV) or MCA. 
* Animals received three  1-mm 3 regressor tumor  fragments  subcutane- 
ously in the inguinal region. Tumor incidence is the number of animals 
with  growing regressor  tumors  4  wk  after  challenge per number  of 
animals challenged (percent in parentheses). The regressor tumors con- 
tinuously grew until death of the animals. 
8 Tumor incidence in the TBA significantly greater than in normal mice 
(P <  0.05). 
I Data represents two independent experiments. 
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Regressor Tumors Growing Out Under the Protection of Progressor Tumors Retain 
their Highly Immunogenic  Regressor Phenotype.  We  have  previously  shown  that 
regressor  tumors  which  upon  rare  occasions develop  into progressively  growing 
tumors  in  normal  animals  are  always  variants  that  have  a  heritable  loss  of  an 
antigen.  In  contrast,  regressor  tumors  growing  out  of  nude  athymic  or  x- 
irradiated  thymectomized  mice  always  retain  their  tumor-specific  antigens  (6). 
This  failure  of the  latter  mice  to  select  for  antigen  loss  variants  seems  to  be  a 1670  MULTIPLE  CANCERS  AND  IMMUNE  SUPPRESSION 
TABLE  III 
Failure of the Tumor-bearing Host to Reject Regressor Tumor Cells Depends 
Upon the Size of the Tumor Burden 
Tumor burden 
Exp.  Number  Duration of  Name of tumor  Total volume  of tumors  growth 
Incidence of 
1591-RE* 
1' 
wk  cm  3  % 
--  o  --  o  0/5  (o) 
1591-PRO  1  2  0.1  0/5  (0) 
1591-PRO  3  2  0.5  4/7  (57)  § 
2 i  --  0  --  0  1/29  (3) 
1591-PRO  1  2  0.1-0.2  2/19 (11) 
1591-PRO  1  2-3  0.4-1.5  11/15 (73)  ~ 
3152-PRO  1  1  0.1-0.2  1/7  (14) 
3152-PRO  1  2  >1.0  5/10 (50)  ~ 
* Mice were engrafted with  1591-PRO at a single site or at three distinct sites.  After the indicated 
duration of growth tile individual tmnors were measured, and then  1591-RE fragments were given 
to all of the animals. 
* Number of mice growing 1591-RE per number of mice challenged (percent in parentheses). Tumor 
incidence assessed  1 mo after challenge. 
Tumor incidence significantly greater than in mice bearing no progressor tumor (P <  0.05). 
Mice were given either 1591-PRO or 3152-PRO. After a period of progressor tumor growth they 
were challenged with three 1  -ram 3 fragments of 1591-RE. Data are pooled from seven experiments. 
! Tumor incidence significantly greater than in mice bearing no progressor tumor (P <  0.01). 
TABLE  IV 
Normal Mice Reject Reisolates of 1591-RE Tumors that Grew Progressively  in  1591-PR0 TBA 
lmnnmodeficient  Name of  Name of reisolate  host*  inoculum 
Tumor incidence 
of reisolates in:* 
Normal mice  Nude mice 
1591 -PRO TBA  1591-RE  1591-PB.1  2/28 (7)  9/9 (100) 
1591-PB.2  0/I0 (0)  4/4 (100) 
1591-PB.3  0/4  (0)  4/4(100) 
1591-PB.4  0/4  (0)  4/4(100) 
1591-PB.5  0/5  (0)  4/4(100) 
Nude  1591-RE  1591-RE (Nu)  0/19 (0)  6/6 (100) 
1591-PRO  1591-PRO (Nu)  30/32 (94)  4/4 (100) 
* 1591  tumors which had grown for at least 4 wk in TBA or nude mice were reisolated, and injected 
as three l-ram 3 fragments into normal or nude mice. 
* Number of tumors growing per number of mice challenged (percent in parentheses) at 5 wk after 
challenge. Tumors grew until death of the host. 
consequence  of  their  severe  immunodeficiency.  We  analyzed,  therefore,  the 
antigenic  phenotype  of  the  tumors  growing  out  of progressor  tumor-bearing 
mice in order  to assess further  the strength  of immunoselection  exerted  by such 
hosts.  Table  IV shows  that  1591-RE  tumors  reisolated  from  1591-PRO  tumor- 
bearing  mice after  a  growth  period  of at  least  4  wk were  regularly  rejected  by 
normal  mice,  showing  that  the  reisolated  tumors  retained  the  1591-RE  pheno- 
type.  To  investigate  whether  these  tumors  also  retained  the  1591-RE  tumor- MULLEN  ET  AL.  1671 
specific antigen, we tested the capacity of these tumor cells to restimulate tumor 
antigen-specific CTL in culture or to serve as targets for such T  cells. Table V 
shows that all the 1591-RE tumors reisolated from TBA could restimulate 1591- 
RE-specific CTL in culture as effectively as the parental  1591-RE  tumor cells, 
whereas  1591-PRO  variants  reisolated  from  normal  hosts  failed to  stimulate. 
The  retention  of the  target antigen  is  further demonstrated in  Fig.  1,  which 
shows that  1591-RE  tumors reisolated from TBA  were as effectively killed by 
1591-RE-specific T  cells as the 159 I-RE tumor, even when reisolated from TBA 
bearing an unrelated progressor tumor, the methylcholanthrene (MCA)-induced 
fibrosarcoma  3152  (Fig.  1,  right).  Thus,  like  severely  immunodeficient mice, 
mice bearing progressively growing tumors neither reject highly immunogenic 
tumor cells nor select for antigen loss variants. 
Regressor Tumors Growing Out Under the Protection of  Progressor Tumors Continue 
to Grow After the Complete Surgical Removal of  the Progressor.  Since the progressor 
tumor  was  necessary  for  the  outgrowth  of the  regressor  and  the  regressor 
retained  the regressor phenotype,  it seemed reasonable  to determine whether 
surgical removal of the progressor tumor would result in the regression of the 
immunogenic tumor. Thus,  15 animals were injected with the 1591-PRO tumor 
and, when the tumors had grown to >0.5 cm  3, the animals were challenged at a 
second  subcutaneous  site  with  a  1591-RE  regressor  tumor.  2  wk  later,  the 
progressor tumor was completely excised surgically. To our surprise,  we found 
in  two independent experiments  that  15  of 15  1591-RE  tumors continued to 
grow (even five 1591-RE tumors <0.2 cm  3) until the demise of the mice 3-6 wk 
later.  Tumors were removed from three  moribund animals; all three retained 
the regressor phenotype being rejected by normal mice in vivo and remaining 
sensitive to the tumor-specific cytolytic cells in vitro (data not shown). 
TABLE  V 
Generation of 1591-RE-specific Immunity by Spleen Cells of Mice Immunized with Reisolates of 
the "Enhanced" 1591-RE Tumors 
Lysis of target cells (percent) 
Inlmtlno- 
Stimulator  1591-PB 
gen*  1591-RE  1591-PRO  2240-RE  1316-RE 
l  2  3  5 
1591-RE  1591-RE  84-+5  $  81+11  94±8  82+4  98+7  9-+1  1+2  7-+2 
1591-PB.2  91-+3  88-+19  96-+1  87+3  81-+2  7±2  3-+0  4-+1 
1591-PB.3  90-+14  80-+7  90-+14  85-+3  84-+9  9-+1  1-+2  0±7 
1591-PRO  2±2  9+2  9--+2  9--.+2  8±4  5-+3  0-+2  6-+5 
1591-PB.2  1591-RE  84+6  89-+ 13  99-+4  86-+9  90-+ 14  8-+3  0-+2  4-+2 
1591-PB.2  80±4  81-+4  98-+7  91+0  99±14  13-+3  3-+1  5-+2 
159l-PB.3  1591-RE  81-+9  87-+16  93±9  83-+6  82-+23  10-+2  1-+2  4+2 
1591-PB.3  80-+5  85-+6  99±6  84-+7  99--.+14  12-+2  2-+1  5-+2 
1591-PB.4  1591-PB.4  80-+4  85±9  99±7  89-+5  99-+16  12-+2  2-+1  2-+1 
1591-PRO  1591-RE  19-+5  11-+5  17-+4  13-+3  14-+4  10--+3  12-+5  11-+4 
1591-PRO  10-+2  19-+5  16-+3  14-+1  10-+3  10-+3  10-+3  10-+3 
* C3H mice were injected with  107 1591-RE, 1591-PB, or 1591.PRO tumor cells subcutaneously.  3 wk later, their spleen  cells were 
restimulated with these tumor cells, as indicated, in a 6 d  MLTC, and then tested against the indicated target cells in a 6 h  51Cr- 
release assay (effector/target ratio, 5:1). 
:~ Mean + SE for four separate experiments. 7
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Facilitation  Is Transferable by Spleen  Cells and Is Not Accompanied  by Generalized 
Immunodeficiency.  We  next  examined  whether  the  tumor-susceptible  state  in- 
duced  by  the  growth  of the  progressor  tumor  could  be  transferred  by  spleen 
cells. The  model we used for these studies was based upon  the previous finding 
(4) that  lethally irradiated  mice reconstituted  with normal  unimmunized  spleen 
cells regularly reject a  subsequent  challenge of a  UV-induced  regressor tumor. 
We tested here whether  cotransfer of spleen cells from TBA  could suppress this 
T  cell-mediated  protection.  Thus,  both  lymphocyte populations  were  injected 
intravenously  into  lethally  irradiated  mice  that  were  then  challenged  with  a 
progressor  tumor.  In  five  experiments  (Table  VI),  we  found  that  spleen  ceils 
from  tumor-bearing  animals could  completely suppress  the  resistance to  1591- 
TABLE  VI 
Spleen Cells  from TBA Suppress the Tumor Resistance Conferred by 
Normal Spleen Cells But Not the Resistance Conferred by Immune 
Spleen Cells 
Sources of transferred  Tumor incidence of 
Exp.  spleen cells*  1591-RE at 
1  Normal  0/5  (0) 
TBA + normal  5/5  (100) 
2  Normal  0/5  (0) 
TBA + normal  5/5  (100) 
Normal  0/5  (0) 
Immune  0/4  (0) 
TBA + normal  5/5  (I00) 
TBA + immune  0/5  (0) 
Normal  1/4  (25) 
TBA  3/3  (100) 
TBA + normal  2/2  (100) 
Immune  0/2  (0) 
TBA + immune  0/2  (0) 
Total  Normal  1/I 9 (4)§ 
TBA + normal  17/17 (100) § 
Immune  0/6  (0) 
TBA + immune  0/7  (0) 
* 800-rad-irradiated mice received intravenously 3  x  107  spleen cells 
from normal, tumor-free mice, 3 x  107 spleen cells from immune mice 
which had rejected 1591-RE fragments 6 wk earlier, 4 x  10 v spleen cells 
from TBA animals having borne the tumor  1591-PRO  for  1 too, or 
mixtures of 3 x  107 normal or immune spleen cells and 4 x  107 TBA 
spleen cells. 
Number of mice with  growing  1591-RE  tumor per number of mice 
challenged (percent in parentheses). Three l-ram  31591 -RE tumors were 
injected subcutaneously at one site and tumor incidence was measured 
at 4 wk. 
Tumor incidence significantly greater in  mice receiving both  normal 
and TBA spleen cells than in recipients of only normal spleen cells (P < 
0.o01). 1674  MULTIPLE CANCERS  AND  IMMUNE  SUPPRESSION 
RE conferred by normal spleen cells but not that conferred by immune spleen 
cells.  Table  VII  summarizes  further  adoptive  transfer  experiments  in  which 
spleen cells from tumor-bearing mice were subjected to various procedures that 
eliminate different cell types, and then assayed for cells suppressing the tumor 
rejection  capacity  of  normal  spleen  cells  when  cotransferred  into  irradiated 
recipients. We found that treatment with anti-Thy-l.2 and complement (C') or 
with  x  irradiation (450  tad)  eliminated suppression, while treatment with  car- 
bonyl iron or with anti-Ly-2.1 and C' did not. The fact that conventional T  cells 
were needed for inducing the suppression is also indicated by the fact that spleen 
cells from nude TBA  fail to cause suppression upon transfer (Table VII, Exps. 
8  and 9). 
As would be expected from our previous results, the suppression mediated by 
spleen cells of 1591-PRO TBA  was not  1591  tumor-specific, since such spleen 
cells also suppressed the rejection of another UV-induced regressor tumor (data 
not  shown).  TBA,  however,  did  not  have  suppressed  responses  to  nontumor 
antigens. For example, five animals bearing a  1591-PRO tumor for 1 mo (tumor 
volume, >1.0 cm  3) were immunized intravenously with 0.2 ml of a  5% (vol/vol) 
suspension  of  sheep  red  blood  cells  in  sterile  phosphate-buffered  saline,  and 
plaque-forming responses were assayed 4  d  later using standard procedures (10). 
TABLE VII 
Phenotype of the Suppressor Cells Isolated  from Tumor-bearing Mice 
Spleen cells transferred* 
Incidence of 1591-RE tumors in experiments  ~ 
1  2  3  4  5  6  7  8  9 
Normal  0/5  0/4  1/3  1/3  0/5  0/4  0/4  0/3  0/5 
Normal + untreated  §  --  --  3/3  3/3  --  --  4/4  3/5  3/5 
TBA 
Normal + C'-treated  5/5  2/4  --  --  5/5  2/3  --  --  -- 
TBA 
Normal + anti-Thy-1 +  1/5  0/4  ....... 
C'-treated TBA 
Normal + carbonyl iron-  --  --  3/3  3/3  ..... 
treated TBA 
Normal + anti-Ly-2 + C'-  ....  4/4  2/4  --  --  -- 
treated TBA 
Normal + 450-rad .......  1/4  ~  --  -- 
treated N  TBA 
450-rad-treated immune  II  ......  0/4  --  -- 
Normal + untreated nude  .......  0/5  0/5 
TBA 
* Recipient mice received 800 tad of x radiation and were then intravenously infused with 3 x  107 
spleen cells from normal, tumor-free mice or 3 ×  107 normal spleen cells plus 4 x  107 (treated  or 
untreated) spleen cells fiom animals bearing progressively growing tumors. 
* Number of mice growing  1591-RE per number of mice challenged.  Mice received three  1-mm  3 
1591-RE fragments subcutaneously. Tumor incidence was measured  1 mo after challenge. 
§ In cases in which TBA spleen cells were treated with antibody and C', "untreated" "FBA ceils were 
incubated with C' only. 
TBA spleen  cells received  450  rad of x  radiation in vitro immediately  before  their infusion. 
Alternatively, a group of mice was reconstituted with 3 x  10  v spleen cells from 1591-RE tumor- 
immune mice that had received 450 rad in vivo to rule out nonselective radiolysis of spleen cells. 
Tumor incidence in group receiving treated TBA spleen cells was significantly less than in group 
receiving untreated TBA spleen cells (P < 0.05). MULLEN  ET  AL.  1675 
The  TBA  had  greater  responses  than  four  age-matched,  tumor-free  control 
animals (218,273 +  26,000 [SEM] vs. 1 1 1,045 +  15,800). Unimmunized animals, 
normal  or  tmnor  bearing,  produced  no  anti-sheep  red  blood  cell  plaques.  In 
other  experiments  (Table  VIII),  we  found  that  the  proliferative  response  of 
spleen  cells from TBA  to alloantigens  was as vigorous as that  of normal  spleen 
cells, and that there was no suppression  of the cytolytic response to alloantigens 
(Fig.  2).  This  is  consistent  with  our  previously  mentioned  finding  (Table  I) 
concerning  the  normal  transplantation  resistance  of tumor-bearing  animals  to 
the allogeneic  P815 mastocytoma. 
Although  TBA  are  not  in  a  state  of  generalized  immune  deficiency,  the 
experiments  do  not  rule  out  the  possibility  of  a  generalized  suppression  of 
responses  to  syngeneic  tumor  antigens.  We  therefore  carefully  examined  the 
specificity  of rejection  of a  syngeneic  regressor  tumor  (e.g.,  the  MCA-induced 
tumor,  1 130-RE)  which,  unlike  most  syngeneic  regressor  tumors,  failed  to  be 
suppressed  by a  given  progressor  tumor  (i.e.,  1591-PRO).  Mice  bearing  1591- 
PRO were simultaneously engrafted with three tumors:  159 l-RE,  1 130-RE, and 
a  mosaic tumor reisolated  from a  nude mouse that had been injected with a  1:1 
mixture  of 1591-RE and  1130-RE cells.  Also challenged  were  1591-RE-immu- 
nized  mice  that  had  subsequently  received  450  rad of x  irradiation;  such  mice 
can  still  reject  tumors against  which  they  have  previously been  immunized  but 
they  are  incapable  of mounting  effective  rejection  responses  de  novo  against 
other tumors (5).  The  results  (Table  IX) show that (a) normal  mice rejected all 
TABLE  VIII 
Proliferative  Responses of Normal and TBA Spleen Cells to Alloantigens 
Average [SH]thymidine uptake  s 
Exp.*  Responder*  (cpm -+ SEM)  Net prolifera- 
tion IL 
Anti-BALB/c  Anti-C3H 
1  Normal C3H  33,509 (+1,059)  4,102 (-+347)  29,403 
TBA C3H  35,728 (-+1,108)  8,727 (-+521)  27,001 
2  Normal C3H  99,489 (-+2,048)  59,229 (+2,292)  40,260 
TBA C3H  81,226 (-+5,995)  35,397 (--.3,346)  45,829 
* Spleens  were sterilely  removed, homogenized with  a  glass grinder,  and suspended  in  medium 
consisting of RPMI 1640 supplemented with 5% fetal bovine serum,  0.1 mM MEM nonessential 
amino acids, 2 mM L-glutamine,  1% penicillin-streptomycin,  and 5 X 10  -5 M 2-mercaptoethanol. 
Stimulator ceils received 2,000 tad of x radiation.  5 x  105 responding cells and 5 x  105 stimulator 
cells were incubated at 37°C in 0.2 ml of medium in flat-bottomed microwells. After 4 d, 2 ~.Ci of 
methyl-[3H]thymidine  in 25 ~.1 of RPMI 1640 was added to each well and harvested  24 h later. 
* Responding spleen cells came from tumor-free C3H mice or from mice that had borne 1591-PRO 
for at least 1 mo. 
Proliferation  of responders against  irradiated  BALB/c or irradiated C3H/HeN spleen  cells was 
measured  on  day 4.  Values  represent  the average uptake of [3H]thymidine  by 8-10  replicate 
cuhures in counts per minute (cpm) (SEM in parentheses)  pulsed on day 4 and measured on day 5 
by liquid scintillography. 
rf Net proliferation:  proliferation against  allogeneic  BALB/c cells -  proliferation against syngeneic 
C3H cells (autoIogous M  LR). In all cases proliferation against BALB/c spleen cells was significantly 
(P < 0.001) greater than against C3H/HeN cells. Responses of normal and TBA ceils do not differ 
significantly (P > 0.05). 1676  MULTIPLE CANCERS AND IMMUNE SUPPRESSION 
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FIGURE 2.  Retention of specific alloreactive CTL responses in  progressor tumor-bearing 
animals. C3H mice were untreated (normal C3H) or challenged with two 1-mm  ~ fragments of 
the  1591 progressor tumor  1591-PRO,  4 wk previously (progressor-bearing C3H).  Spleen 
cells from these animals were stimulated in culture with irradiated (2,000 rad) BALB/c (H-2 a, 
closed symbols) or C3H (H-2 k, open symbols) spleen cells for 6 d and then tested in a 6 h ~lCr- 
release assay against P815 (H-2d; O, O), K101-RE (H-2a; I, D), 1591-RE (H-2k; &) or EL4 (H- 
2b; V) target cells. Data represent the mean + SE for four separate experiments. The yield of 
viable cells recovered from day 6 for BALB/c stimulated cultures was 41 -  4% of the original 
spleen cell input for normal C3H spleen cells and 30 -  3% for progressor-bearing C3H spleen 
cells. 
three grafts, (b) the  1591-PRO  TBA  grew out the  1591-RE  and mosaic tumors 
but rejected  1130-RE, and (c) the  1591-RE-immunized and then irradiated mice 
grew  out  the  1130-RE  and  mosaic  tumor  but  rejected  1591-RE.  The  mosaic 
tumors  were  reisolated and  their composition analyzed.  Fig.  3  shows  that  cells 
reisolated from the tumors emerging  from the  1591-PRO  TBA  challenged with 
the mosaic tumor  were as susceptible to lysis by  1591-RE-specific cytolytic cells 
as a  homogeneous  population of 1591-RE  control cells. In contrast,  cells reiso- 
lated from  tumors  emerging  from  irradiated  1591-RE-immune  mice and  chal- 
lenged with  the  mosaic were as resistant to  lysis as homogenous  populations of 
1130-RE  cells,  indicating  that  only  these  cells  survived.  Lysis of control  cells 
reisolated from a  nude  mouse injected with the  mosaic tumor  was intermediate 
(Fig.  3),  indicating that  in  these  mice cells of both  tumors  survived.  Together, 
the experiments  show that TBA  do not have a  generalized immune  suppression 
to all syngeneic tumors. 4 However,  the  failure of 1591-PRO  TBA  to  suppress 
4 The resistance of the 1130-RE tumor rejection to the suppression in  1591-PRO TBA does not 
seem to be due to an  increased immunogenicity of the  1130-RE  tumor as compared with  other 
regressor tumors that are susceptible to this suppression; at least, rejection of 1130-RE  is not more 
resistant to immune suppression by graded doses of x rays than rejection of other regressor tumors. MULLEN  ET  AL.  1677 
TABLE  IX 
Growth of 1591-RE,  1130-RE, and Mosaic  1591-RE/1130-RE  Tumors in Tumor-bearing 
and Immune Irradiated Animals 
Host 
Tumor incidence  I 
159 I-RE  1130-RE  Mosaic  ~ 
Normal  0/5 (0)  0/5 (0)  0/5 (0) 
Normal given 450 rad*  2/2 (100)  2/2 (100)  2/2 (100) 
1591-PRO TBA*  9/9 (100)  0/9 (0)  9/9 (100) 
1591-RE-immune given 450 rad  §  0/8 (0)  8/8 (100)  8/8 (100) 
* Mice received 450 rad of gamma radiation 24 h before tumor challenge. 
* Mice had borne 1591-PRO for 3 wk. 
Mice had rejected  1591-RE  fragments  1  mo earlier and received  450  rad 24  h  before  tumor 
challenge. 
II Number of animals with growing tumors at each particular injection site 1 mo after challenge per 
number of animals challenged (percent in parentheses). All mice with tumors at  1 mo died from 
progressive tumor growth. Three  l-ram  3 fragments of each tumor were injected subcutaneously 
into each mouse; 1130-RE was placed on one flank, 1591-RE on the other, and the mosaic on the 
ventral midline. 
5  x  106  1591-RE cells and 5  x  106  1130-RE cells were mixed and injected into a  nude mouse. 
After 3 wk the tumor was removed, minced, and injected into these mice. 
the rejection of the syngeneic tumor  1130-RE  is one of the exceptions to the 
general  rule  that  TBA  usually  facilitate  the  outgrowth  of other  syngeneic 
regressor tumors, as shown earlier in this report. 
Discussion 
This study shows that the presence of an established tumor can favor decisively 
the outgrowth  of a  second tumor  at  a  different location.  This  enhancement 
appears  to  be a  consequence of an  immunological suppression  caused by the 
established tumor, since the potentially malignant cells forming the second tumor 
in  the TBA  do not normally grow in  immunocompetent mice.  Furthermore, 
theta-bearing  spleen  cells  from  TBA,  but  not  spleen  cells  from  nude  TBA, 
suppressed tumor rejection by normal spleen cells in adoptive transfer experi- 
ments. The suppression was caused by several different progressor tumors and 
affected the rejection of several different regressor tumors regardless of whether 
they  had  been  induced  by  UV  radiation.  This  broad  crossreactivity of the 
described T  cell-mediated suppression  is  in  striking  contrast to  cytolytic and 
helper T-mediated immunity, which we found to be exceedingly tumor-specific 
for individual tumors despite extensive testing for crossreactivity (7, i 1, 12, and 
unpublished results). The type of suppression described here also appears to be 
different from another type of tumor-induced immune suppression that affects 
immune rather than nonimmune T  cells and which has specificity for an individ- 
ual tumor (13-16).  In many respects, however, the type of suppression we have 
observed in TBA simulates the suppression caused by UV radiation (5,  17-21). 
For example, UV-induced suppression also (a) permits the outgrowth of highly 
immunogenic UV-induced regressor tumor cells, (b) is not individually tumor- 
specific and affects UV-induced as well as non-UV-induced tumors, (c) does not 
affect allogeneic or other humoral responses, (d) is transferable by Ly-2- T  cells, 1678  MULTIPLE  CANCERS  AND  IMMUNE  SUPPRESSION 
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FIGURE 3.  Lysis  of mosaic tumors  by  1591-RE-specific CTL. After  adaptation  of mosaic 
tumors to tissue culture they were used as targets for 1591-RE-specific cytolytic cells in a 6 h 
51Cr-release assay. 1591-PRO TBA or  1591-RE-immune x-irradiated  (500 tad)  mice were 
challenged with fragments of 1591-RE, 1130-RE, or a mosaic tumor composed of approxi- 
mately equal parts of 159 I-RE and  1130-RE, generated  by coinjection of the two cell lines 
into the same site in nude  mice. One month  later, the progressively growing tumors  were 
excised. Tissue culture stock 1591-RE and  1130-RE cells were used as control targets. 
and  (e) suppresses tumor rejection  mounted  by naive,  unimmunized  lymphoid 
cells but not the protection conferred by lymphoid cells from mice preimmunized 
to a particular tumor. There are even certain similarities in the exceptions to the 
crossreactivity of the  two types of suppression,  such as the failure of the  MCA- 
induced  regressor tumor  1 130-RE  to be enhanced  by UV-induced  suppression 
(22)  or  by  TBA  bearing  certain  progressor  tumors.  Together,  these  rather 
striking similarities suggest that progressively growing tumors and UV irradiation 
might bring about a  similar suppression of the immune system.  Indeed,  in both 
cases, the immune system is confronted with a  large number of altered cells, and 
it might be that  UV  irradiation  and  neoplastic  transformation  of cells leads to 
the  expression  of gene  products  that  suppress  the  immune system in  a  similar 
way. Consistent with such a notion are experiments showing that transplantation 
of UV-irradiated  skin  can  suppress tumor rejection  (23).  The fact that  tumors 
other  than  those  induced  by UV radiation  also induce,  and  are  susceptible  to, 
this type of suppression indicates its general relevance to tumor immunology. 
The  tumor-induced  immune  suppression  in  the  TBA  can  be  even  stronger 
than that induced by UV irradiation,  because UV-irradiated hosts still select for 
antigen  loss  variants  (1 1)  while  TBA  do  not.  This  difference,  however,  may MULLEN ET  AL.  1679 
simply be due to the larger numbers of altered cells to which the TBA is exposed, 
since the degree of suppression was clearly dependent upon the size of the tumor 
burden. Thus, only after the first tumor had reached a critical (>0.5 cm  s) size 
was the host's ability to reject highly immunogenic cells abrogated, and the cells 
were  able  to  develop  into  a  second  tumor  without  undergoing  measurable 
immunoselection by the host. The failure of immune selection was indicated by 
the fact that these second tumors were rejected regularly upon further trans- 
plantation to normal syngeneic hosts at any testable dose of tumor fragments or 
cells (>1  x  108  cells).  The  observed  strength  of suppression  and the  lack  of 
immunoselection raise the possibility that second primary malignancies in man 
may be more antigenic than the first cancer and thus may be more susceptible 
to passive immunotherapy. For active immunotherapy, however, the observed 
strength and  crossreactivity of the immune suppression  may well represent  a 
major difficulty. For example, it has been suggested that immunogenic regressor 
tumor variants  obtained  after  in  vitro  mutagenesis could  be  used  for active 
immunotherapy (24,  25).  If our results are generalizable, such an approach is 
not likely to succeed in tumor-bearing individuals since such regressor variants 
might  both  grow  out  in  the  patient  and  even  maintain  the  tumor-induced 
suppression. We observed that this maintainance of suppression occurred even 
after the first tumors were completely removed.  Furthermore, we found that 
the second regression tumor continued to grow, even though some of them had 
reached sizes of only 0.2 cm  s or less at the time of removal of the first tumor. 
This  small  size  might  correspond  to  a  size  that  is  clinically undetectable  in 
humans.  At present,  we  do  not  know  how the  second (regressor)  tumor can 
maintain the suppression induced by the progressor tumor, but we have recently 
found that this suppression can be maintained in serial passage through animals 
bearing only the regressor tumor (C.  A.  Mullen, unpublished observation).  It 
will  be  important to  learn  how  to  overcome this  immune suppression  in  the 
tumor-bearing host and to accomplish rejection of these extremely immunogenic 
tumors after they are  well established, since otherwise the outlook for active 
immunotherapy of other cancers, many of which may be less immunogenic, is 
poor.  One possibility is to develop regimens by which tumor immunity can be 
generated de novo from the tumor-bearing host's lymphocytes in vitro, followed 
by adoptive transfer into the tumor-bearing host (26),  since we find that T  cells 
from immunized mice are resistant to the suppression. 
Several different mechanisms, such as increased genetic susceptibility to cancer 
development (27)  or heavy exposure to carcinogens, may also cause the devel- 
opment of multiple malignancies in the same host; however, our model using 
genetically  inbred  mice  and  cells  that  have  previously  encountered  a  given 
carcinogen allows us to describe another independent pathway which is mediated 
by immune suppression.  Although the specificity of the described suppression 
was rather broad, affecting most of the different tumors tested, there was  no 
evidence for a  generalized immune suppression in the TBA. The suppression 
did not affect allograft rejection in vivo, proliferative and cytolytic responses to 
alloantigens in vitro, nor humoral responses to sheep red blood cells;  further- 
more, there were exceptional combinations in which a  given progressor tumor 
failed to enhance the outgrowth of a given regressor tumor. For example, TBA 1680  MULTIPLE CANCERS AND IMMUNE SUPPRESSION 
growing out 1591-RE still  rejected the syngeneic tumor  1130-RE not only at an 
anatomically distinct site but even admixed within the same (mosaic) tumor. 
At present,  we can  only speculate about which antigens  are  involved in  the 
crossreactive suppression  of tumor-bearing  animals.  For example,  immunosup- 
pressive molecules that are shared by many murine and human  tumors such as 
the P15E protein could be involved (28, 29). However, we have no evidence for 
the existence of a single antigen shared between the progressor tumors causing 
suppression and the suppressed regressor tumors, and it is equally possible that 
the suppressor T  cells do not react with tumor antigen but instead with tumor- 
reactive T  cells (30). The fact that certain  tumors are distinct exceptions to the 
general rule of cross-suppression will help us to separate the observed suppression 
from other modes of immune suppression and to identify the responsible mech- 
anism. 
Summary 
We demonstrate that tumor-bearing hosts permit the outgrowth of"potential]y 
malignant"  cells  that  are  located  at  a  different  site.  These  second  cancers 
continued to grow and kill their hosts even though they retain the "premalignant" 
phenotype,  even  after  removal  of  the  original  malignancy.  The  potentially 
malignant  cells used in these experiments were ultraviolet light- or methylcho- 
lanthrene-induced  regressor tumor cells that  are rejected regularly by normal 
mice  at  any  testable  dose,  and  only  form  progressive  tumors  in  immunosup- 
pressed individuals.  The immunological rejection of these highly immunogenic, 
potentially malignant cells was suppressed by Thy-1 +, Ly-2-, nonadherent, radio- 
sensitive suppressor cells in the tumor-bearing mice. These suppressor cells were 
absent in nude tumor-bearing mice. Unlike helper and cytolytic T  cell-mediated 
responses,  which  are  exquisitely  tumor  specific,  the  suppression  caused  by a 
progressively  growing  tumor  was  crossreactive  among  many  syngeneic,  inde- 
pendently derived tumors induced  by different carcinogens.  However, T  cell- 
mediated immune responses to alloantigens, allogeneic tumors, certain syngeneic 
tumors,  and  humoral  responses to xenogeneic red  blood cells were normal  in 
these  mice.  The  immune  suppression  in  the  tumor-bearing  animals  closely 
simulated  that  induced  by ultraviolet  light  irradiation,  and  both  types of sup- 
pression might therefore share common mechanisms. Our findings may contrib- 
ute to understanding the growth, development, and possible control of multicen- 
tric malignancies and add a precaution to the potential use of strongly immuno- 
genic tumor variants  for active immunotherapy  in  hosts bearing  less immuno- 
genic tumors. 
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